- REVLIMID(R) Marketing Authorization Application (MAA) Accepted by EMEA for Review
Celgene is seeking authorization to market REVLIMID as a treatment for transfusion-dependent anemia due to certain myelodysplastic syndromes (MDS). REVLIMID also has been designated as an Orphan Medicinal Product in the EU for the treatment of multiple myeloma (MM). Celgene expects to file its supplemental New Drug Application and MAA for REVLIMID in previously treated patients with relapsed and refractory MM to the FDA in fourth quarter 2005, and to the EMEA in first quarter 2006. (from PR Newswire)
- IMF Honors Dr. David Agus for Use of World's Most Powerful Magnets to Unlock Secrets of Cancer Treatment
By using some of the world's most powerful superconducting magnets to separate the proteins in a drop of blood, Dr. Agus is engaged in a breakthrough study to help determine which myeloma patients are best able to benefit from bone marrow transplants. Dr. Agus will be honored at the 15th annual Ribbon of Hope Gala, November 12, at the Beverly Hilton Hotel. (from PharmaLive)
- Lights, Camera, Action, Cure! It is almost time for the GALA!
If you are in the Los Angeles area, or if you would like to be, why not get out your evening togs and dancing shoes and come to the 15th Anniversary Ribbon of Hope Gala - November 12, 2005 at the Beverly Hilton. Let's go over the reasons you should join us at the Gala: Great food. Rockin' band. Worthy honoree (see above). Adorable auction items. (Yes, I said adorable--We have puppies!!) Good cause...wait, make that VERY good cause. It's not too late to call and reserve a place for the IMF's big fundraiser. Call Rolake at the IMF (800) 452-CURE and take that tux to the cleaners.
- NY actress pulls show together to benefit IMF
New York actress Jackie Urso Comisar will return to Pittsburgh for a worthwhile cause. Although she is no stranger to volunteering her time and talent through VocalEase, a Broadway actor and professional group, she is returning for a benefit show that hits close to home. Comisar will host the Heart and Music: a cabaret for a cure on Saturday, Nov. 5, at 9:30 p.m. to benefit the IMF. (from TribTotalMedia)
- Combination of Drugs Shows Promise for Treatment of Multiple Myeloma
The combination of melphalan, prednisone, and thalidomide produced a quick and lasting response in newly diagnosed multiple myeloma patients, according to a study published in the journal Cancer. (from CancerConsultants)
- Living Loudly
Before being diagnosed with multiple myeloma, Nicholas Baldukas was a large, very strong man who spent his days building houses and playing tennis three times a week. (from the Journal Times)
- Shopping for the Holidays and the Cure
Yes, it's that time of year, when we're all looking at the calendar and counting up how many more shopping days we have left until Christmas or Hannukah. Here's a way to make your already busy life less hectic. All you have to do is go to the Helping the IMF section of the web site (www.myeloma.org) and order just the gift you want. On the left side you will see a heading called "Shop For The Cure" and there you will find shopping opportunities such as Barnes & Noble, Amazon.com, buy.com, FTD.com and
1-800-Flowers.com (for decorating those festive holiday tables), Lands' End, Macy's, Sharper Imagine and Walmart, to name a few. The IMF receives a portion of everything that is bought through our web site, so not only are you saving money on gas by not driving from store to store, you're helping to raise money for myeloma too. If you don't find anything there, click on our "Events" tab, and scroll down through the items that are designed by our IMFers, such as Pam Larsen's Multiple Colors For Multiple Myeloma, beautiful personalized keychains and earrings, or Kristi Difford's gorgeous personalized jewelry. There are also scenic cards designed by Irma Catlett for the IMF and wine bottle vests for dressing up that holiday dinner gift of wine. And of course, there are the multiple myeloma wrist bands, which you can tie into your package ribbons, and the Ribbon of Hope pin for giving the gift of hope. And all from the comfort of your laptop! So start early – avoid the crowds – and be the first in your neighborhood to cross all those items off your list.
WHAT'S NEW IN RESEARCH
- Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma
Paul Gerard, Guy Richardson, Bart Barlogie, James Berenson, Seema Singhal, Sundar Jagannath, David Irwin, S. Vincent Rajkumar, Teru Hideshima, Hugh Xiao, Dixie Esseltine, David Schenkein, and Kenneth C. Anderson, for the SUMMIT Investigators
Blood 2005;106 2977-2981
- Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2
Takashi Oshima, Masahiro Abe, Jin Asano, Tomoko Hara, Kenichi Kitazoe, Etsuko Sekimoto, Yoichi Tanaka, Hironobu Shibata, Toshihiro Hashimoto, Shuji Ozaki, Shinsuke Kido, Daisuke Inoue, and Toshio Matsumoto
Blood 2005;106 3160-3165
- Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity
Kai Sun, Danice E. C. Wilkins, Miriam R. Anver, Thomas J. Sayers, Angela Panoskaltsis-Mortari, Bruce R. Blazar, Lisbeth A. Welniak, and William J. Murphy
Blood 2005;106 3293-3299
- Anti-myeloma activity of heat shock protein-90 inhibition
Constantine S Mitsiades, Nicholas S Mitsiades, Ciaran J McMullan,Vassiliki Poulaki, Andrew L Kung, Faith E Davies, Gareth Morgan, Masaharu Akiyama, Reshma Shringarpure, Nikhil C Munshi, Paul G Richardson, Teru Hideshima, Dharminder Chauhan, Xuesong Gu, Charles Bailey, Marie Joseph, Towia A Libermann, Neal S Rosen, and Kenneth C Anderson
Blood published 18 October 2005, 10.1182/blood-2005-03-1158
- Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study.
Hung IF, Wu AK, Cheng VC, Tang BS, To KW, Yeung CK, Woo PC, Lau SK, Cheung BM, Yuen KY.
Clin Infect Dis. 2005 Aug 1;41(3):291-300. Epub 2005 Jun 23.
- Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African-American and White veterans in the U.S
Ola Landgren, Gloria Gridley, Ingemar Turesson, Neil E Caporaso, Lynn R Goldin, Dalsu Baris, Thomas R Fears, Robert N Hoover, and Martha S Linet
- A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo
Elke Pogge von Strandmann, Hinrich P. Hansen, Katrin S. Reiners, Roland Schnell, Peter Borchmann, Sabine Merkert, Venkateswara R. Simhadri, Andreas Draube, Marcel Reiser, Ingvill Purr, Michael Hallek, and Andreas Engert
Blood published 6 October 2005, 10.1182/blood-2005-05-2177
- Potential protective action of pituitary adenylate cyclase-activating polypeptide (PACAP38) on in vitro and in vivo models of myeloma kidney injury
Akira Arimura, Min Li, and Vecihi Batuman
Blood published 4 October 2005, 10.1182/blood-2005-03-1186
- Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy
Morie A. Gertz, Martha Q. Lacy, Angela Dispenzieri, Philip R. Greipp, Mark R. Litzow, Kimberly J. Henderson, Scott A. Van Wier, Greg J. Ahmann, and Rafael Fonseca
Blood 2005;106 2837-2840
- CLINICAL TRIALS
- VELCADE® trials
- THALOMID® trials
- TRISENOX™ trials
- REVLIMID™ trials
- DOXIL® trials
- A Phase I/II trial of VQD-001, a therapy that targets a class of enzymes, has opened to test the drug's safety, tolerability, and efficacy. The trial is taking place at the Cleveland Clinic Taussig Cancer Center for patients with relapsed and refractory solid tumors, lymphoma, and myeloma.
- A new phase I study has opened to evaluate ATN-224 in patients with advanced hematologic malignancies. ATN-224 is an oral drug (capsule) that inhibits CuZn Superoxide Dismutase (SOD1). ATN-224 is currently being evaluated in two Phase I trials; one involving patients with solid tumors in the UK, and the other involving patients with blood-related cancers at multiple centers in the US.
- Phase I/II dose-escalating, multi-center, non-comparative, open label study designed to assess the safety and efficacy of Defibrotide with the MPT regimen as salvage treatment in advanced refractory MM patients. It will open at approximately 10 centers in Italy under the guidance of principal investigator and IMF Scientific Advisor Prof. Mario Boccadoro, Division of Hematology, University of Turin.
If you would like more information about any clinical trial, you can call the IMF Hotline at 800-452-CURE. The Myeloma Matrix has a current list of all myeloma trials from pre-clinical to recently FDA approved. If you would like to browse trials currently open for enrollment, visit the Clinical Trials page of the IMF web site. Among the links, you will find EmergingMed, with whom the IMF has entered into a partnership to assist you in matching trials to your particular patient profile (i.e., stage of disease, previous treatment, how well you are able to carry out the activities of daily living, etc.) and by doing so, increase your chances of being eligible. You can also learn more about clinical trials by reviewing materials from the National Cancer Institute.
UPCOMING SEMINARS AND CLINICAL
UPCOMING EVENTS AND EXCITING OPPORTUNITIES
The HealthWell Foundation has recently opened the
Multiple Myeloma fund to help even more patients gain access to the best
health care available. You can contact them at (800) 675-8416 or
Access Network Foundation (PANF) provides copay assistance for myeloma. Thalomid is the MRDD product covered for this condition. The PANF formerly just covered qualified myeloma patients' erythropoietin alpha expenses. Patients or healthcare providers may initiate the application process. Applications must be completed by both physician and patient, and income verification is required. Their phone number is 1-866-316-7263.
SHOP FOR THE IMF
Shop at leading internet retailers (e-tailers) like Amazon.com, and they will donate a portion of your purchase to the IMF. To do this, you access their site via special URLs we have set up. For Amazon, it's http://amazon.myeloma.org instead of amazon.com. It will take you to the same place, but any purchase you make during that visit will be credited to the IMF. Visit our Shop for the IMF page at http://shop.myeloma.org for express links to other popular etailers who will donate a portion of your purchase to the IMF.
|Our own Rosanne Kalick, who co-leads the Westchester, NY support group, has written a book titled "Cancer Etiquette: What to do, what to say, when someone you love has cancer." You can order now at a discount.
"The more I investigated, the more convinced I became that most people do not know what to say or what to do when someone they know or love has cancer. This book will help them find words that will not offend or hurt, but will help to comfort. This book will enable them to perform simple acts of loving-kindness that are blessings to the patient."
New! Multiple Colors for Multiple Myeloma Keychains and Earrings
The gift-giving holidays will be upon us sooner than we think. And there are always birthdays, anniversaries, and "just because you're you" occasions. Here are two new items to help support the International Myeloma Foundation: colorful keychains and chandelier earrings of Swarovski crystals.
Imagine Moving Forward is the theme of the IMF's popular myeloma bracelet. At medical conferences and patient & family seminars we see people wearing them in honor, celebration, or in memory of a loved one. They're only $1 each in sets of 10, so order them for everyone you know who has been touched by myeloma. Order them on the web. If you have questions about the bracelets or would like more information, contact Suzanne Battaglia at (800) 452-2873, ext. 227, or SBattaglia@myeloma.org.
Multiple Myeloma Awareness Jewelry
The response has been great for the new garnet bracelet IMFer Kristi Difford has added to her line of beautiful custom bracelets to honor those who have joined the struggle against multiple myeloma. Check it out.
See more exciting ways to help the IMF continue its important work in education, support and research.
|Help Us Help Others...
As a non-profit organization, the
IMF is completely dependent on the support of our members. Tax-deductible
donations in honor of a friend or family member make great gifts and are a
wonderful way to celebrate a special occasion. You can donate
online or by calling the IMF at (800) 452-CURE. We sincerely thank you
for your support.